Engflag

Ranitidine Arrow

Quick links to important sections

Ranitidine Arrow

Ranitidine Arrow_EN

Method of action: Antiulcer, Drugs For Acid Related Disorders

Treatment option: Duodenal Ulcer, Dyspepsia, Heartburn, Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Stress, Esophagitis, Erosive Esophagitis, Stomach Ulcer

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ranitidine Arrow

Quick Facts

Property Description
Active ingredient Ranitidine Hydrochloride
Form Film-coated tablets, oral solution, solution for injection
Pharmacological class Histamine H2-receptor antagonist (H2-blocker)
Common use Reducing stomach acid and relieving related irritation
Origin Synthetic compound

What Type of Medicine is Ranitidine Arrow?

Ranitidine is a single-component product with the active ingredient Ranitidine Hydrochloride as its core substance. This medicine is a synthetic compound classified pharmacologically as a Histamine H2-receptor antagonist, commonly known as an H2-blocker. This classification means the medicine is specifically designed to reduce the quantity of acid produced within the stomach. H2-blockers work by decreasing the amount of acid the stomach makes, a mechanism utilized for providing sustained relief from acid-related discomfort.

Composition and Physical Form of Ranitidine

The active ingredient, Ranitidine Hydrochloride, is formulated alongside standard pharmaceutical excipients, not a natural base. Ranitidine is presented in multiple high-level dosage forms, including the common film-coated tablets for oral administration, as well as an oral solution and a solution for injection. This availability confirms the medicine's use through both oral and parenteral administration routes, ensuring flexible management of gastric acid secretion across various medical settings. The drug possesses properties as an acid-reducing agent with anti-secretory effects.

How Does Ranitidine Help the Body?

The primary function of this medicine is to alleviate discomfort and irritation caused by excessive stomach acid by promoting a less corrosive environment. Ranitidine achieves this through its highly specific action: it performs competitive antagonism of the histamine signal that triggers acid production. By blocking the specific H2-receptors on the stomach lining cells, the medicine significantly reduces the quantity and concentration of gastric acid secretion. This mechanism is frequently applied in managing the burning sensation often associated with temporary episodes of indigestion.

Regulatory References

  1. Ranitidine: MedlinePlus Drug Information
  2. Ranitidine: LiverTox (NIH)
  3. Ranitidine-containing medicinal products - referral

What side effects are possible with Ranitidine Arrow?

Possible Side Effects and Safety Information

The safety profile for ranitidine is significantly structured by the former regulatory actions taken globally concerning the presence of a probable human carcinogen, N-nitrosodimethylamine (NDMA), which led to market suspensions and recalls.

Beyond this contamination risk, officially documented adverse reactions are categorized by frequency and affected body system, detailing the medicine's intrinsic risks. The frequency classifications in regulatory documents include Rare (e.g., blood count changes, severe skin reactions, acute pancreatitis) and Very Rare (e.g., severe heart rhythm disturbances, specific forms of hepatitis).

Key System-Organ Classes involved include the Hepatobiliary System (with rare reports of hepatitis, jaundice, or elevated liver enzymes) and the Nervous System (with reports of headaches, dizziness, and reversible mental confusion, especially in elderly or severely ill patients).

Serious Adverse Reactions that are documented in official sources include anaphylaxis (severe allergic reaction), agranulocytosis (severe reduction in white blood cells), and forms of hepatitis (liver inflammation).

Safety Restrictions and Population-Specific Notes

The medicine is contraindicated in patients with a history of acute porphyria (a metabolic disorder) due to the risk of precipitating an attack. Caution is required in patients with pre-existing renal (kidney) or hepatic (liver) impairment, often necessitating a dosage adjustment due to altered elimination of the drug. Additionally, official labeling notes that relief of symptoms does not exclude the possible presence of an underlying gastric malignancy.

Overdose and Emergency Response

Ranitidine Arrow Overdose and When to Seek Help

Overdose Scope

Official regulatory information indicates that due to the specific action of ranitidine, no particular problems are expected following overdosage. Despite this low assessment of primary drug toxicity, the regulatory guidance strictly advises taking immediate action.

Documented Overdose Manifestations:

Manifestation Regulatory Statement
Acute Symptoms No particular problems are expected.
Serious Outcomes Not explicitly detailed as a primary focus in the overdose section.

Emergency Response

Immediate medical help is required for any suspected overdose, even if the individual has no immediate symptoms. The official instructions are to contact a healthcare practitioner, a hospital emergency department, or a regional Poison Control Centre immediately.

Overdose Management:

Official documentation specifies that management should consist of symptomatic and supportive therapy as appropriate for the individual's condition. In circumstances where removal of the medication may be necessary, the drug may be removed from the plasma by haemodialysis.

When to Seek Urgent Help (Label-Derived Phrasing):

  • Immediately, in the event of overdose, even if there are no symptoms.

Connection to Overdose Profile

The regulatory overdose profile emphasizes the need for an immediate emergency response (contacting a professional or center) as the first priority, regardless of the drug's specificity or the lack of expected problems. This approach ensures that supportive measures are available and initiated promptly, defining the condition for seeking help as any over-ingestion, not just the presence of symptoms.

Therapeutic Uses of Ranitidine Arrow

What Ranitidine Arrow Treats: Main Uses and Benefits

This medicine is commonly used for a variety of conditions related to heightened physiological activity caused by excessive stomach acid. Ranitidine provides action that contributes to symptom stabilization across multiple domains.

This medication is applied to address symptom clusters that may become intense or disruptive, and is relevant for managing symptoms that interfere with daily comfort, including the burning sensations of heartburn and general acid indigestion (dyspepsia). Its use contributes to improved comfort during periods of heightened symptoms, helping patients cope more steadily with difficult episodes. It is also commonly used across conditions presenting with localized discomfort and physical damage, such as active gastric and duodenal ulcers and erosive esophagitis caused by chronic reflux.

The medicine is commonly used in conditions characterized by periods of heightened symptoms, such as long-term conditions like Gastroesophageal Reflux Disease (GERD). It is also relevant in clinical settings for prophylaxis, such as when managing the risk of ulcer formation in patients taking certain medications like NSAIDs or those under high systemic stress.

“This application helps address groups of symptoms that may intensify over time, supporting the patient during difficult episodes.”

Quick Fact: Relief for Acid-Related Symptoms

Property Description
Primary Benefit Symptom stabilization and support for addressing inflammatory or irritative states
Target Symptoms Heartburn, dyspepsia, ulcer-related pain, acid irritation
Target Conditions Peptic ulcers (gastric/duodenal), GERD, Erosive esophagitis
Contextual Use Prophylaxis (e.g., NSAID injury prevention), chronic acid control

Regulatory References

  1. NIH MedlinePlus overview of Ranitidine's Uses

Eligibility and Restrictions for Use

The eligibility profile for ranitidine products has been severely affected by the withdrawal of most formulations from major markets (e.g., FDA, EMA) due to the risk of unacceptable levels of the impurity N-nitrosodimethylamine (NDMA).

Populations That Must Not Use This Medicine (Contraindications)

Classification Restriction
Hypersensitivity Patients with a known allergy or hypersensitivity to ranitidine or any of the product's excipients.
Acute Porphyria Patients with a history of acute porphyria, as ranitidine may precipitate acute attacks.

Use Requires Special Caution or Restriction

Classification Restriction/Limitation (If Currently Available)
Renal Impairment Patients with severe renal impairment (creatinine clearance < 50 mL/min) require an official dosage reduction due to prolonged drug elimination.
Children Use is not recommended or is restricted in children under 16 years of age in some product labels due to limited data.
Pregnancy/Lactation Safety has not been established. Use is only advised if considered essential after weighing potential benefits against possible hazards, as the drug is secreted in breast milk.

Note on Availability: The primary constraint on eligibility is the lack of authorization for most ranitidine products; use is only permitted for individuals prescribed or utilizing a specific ranitidine formulation that is currently available and officially approved in their regulatory jurisdiction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information outlines several key interaction categories for Ranitidine Arrow based on its effect on gastric pH and its competition for the renal organic cation transport system.

Interaction Scope and Mechanisms

Feature Details (Based on Official Regulatory Documentation)
Medicinal product categories with documented interactions Agents whose absorption is significantly dependent on gastric pH (e.g., certain antifungals, certain antiretrovirals), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Coumarin anticoagulants (e.g., Warfarin), drugs eliminated by the renal organic cation transport system (e.g., Procainamide).
Specific interacting medicines (if explicitly listed) Procainamide, N-acetylprocainamide, Warfarin, Ketoconazole, Atazanavir, Delavirdine, Gefitinib, Midazolam (oral), Triazolam, Sucralfate (at high doses).
Mechanistic basis of interactions Alteration of gastric pH (leading to impaired absorption), Inhibition of renal organic cation transport system (reducing renal excretion), Altered prothrombin time (with coumarin anticoagulants).

Interaction Constraints

Constraint Detail (As Defined in Official Documents)
Timing-based interaction rules High doses of oral Sucralfate (e.g., 2g) should be administered at least 2 hours after ranitidine administration.
Population-specific interaction notes In patients with renal impairment, plasma levels of ranitidine are increased; monitoring is required when co-administering drugs eliminated via renal clearance.
Interaction-related restrictions Do not use ranitidine with other products containing ranitidine or other H2 blockers.

These interactions necessitate careful management of co-administered agents to prevent clinically significant changes in drug exposure or effect.

Mechanism of Action

Reversible Histamine H2-Receptor Antagonism

Ranitidine acts within domains involving receptor-mediated signaling by competitively and reversibly binding as an antagonist to histamine H2 receptors located on the basal membrane of gastric parietal cells. This molecular engagement prevents the binding of endogenous histamine, thereby modulating the H2-mediated signaling pathway that triggers acid secretion.

Modulation of Gastric Acid Secretion Cascades

The drug modifies the early molecular steps within the cell by suppressing the histamine-dependent signaling cascade. This inhibition ultimately reduces the activation signal to the proton pump ( H^+/ K^+-ATPase), the final enzyme responsible for transporting acid into the gastric lumen.

Physiological Adjustment in the Digestive System

By reducing the intracellular processes that drive acid output, ranitidine modulates the activity within the targeted gastric signaling pathways. The system-level physiological consequence is a decrease in both basal and nocturnal gastric acid output and a proportional reduction in the total hydrogen ion concentration of the gastric fluid.

Dosage and Administration Information

How to Use Ranitidine Arrow: Administration Guidelines

Administration of this medicine follows specific parameters regarding route, dosage, frequency, and duration. It is provided for both oral intake (as tablets, capsules, or solution) and parenteral routes, specifically Intravenous (IV) injection/infusion or Intramuscular (IM) injection, allowing for use in both outpatient and acute settings.

Standard oral regimens for active treatment, such as for ulcers, typically involve a 150 mg dose taken twice daily or a single 300 mg dose taken once daily, often scheduled at bedtime or after the evening meal. For acute IV use, the standard dose is 50 mg administered every 6 to 8 hours. The maximum labeled dose for hypersecretory conditions is specified to be 6 grams per day in divided oral doses.

Feature Procedural Instruction
Preparation Effervescent forms must be dissolved in a full glass of water before consumption; IV solutions require dilution before slow administration.
Dose Adjustments Patients with renal impairment (creatinine clearance <50 mL/min) must receive a reduced oral dose of 150 mg every 24 hours.
Duration Acute treatment courses are typically limited to 4 to 8 weeks. Non-prescription use is limited to 14 days.

The overall use protocol is structured by these defined timeframes and administration methods. The protocol includes specific dose modifications for physiological status and precise preparation steps for certain formulations, reflecting the standardized use of the medicine across various applications.

Recent Clinical Evidence

Ranitidine Arrow: Recent Clinical Evidence

Ranitidine is a type of medicine known as a histamine H2-receptor antagonist (H2 blocker). Its primary mechanism, confirmed by clinical studies, is to reversibly block histamine receptors on stomach cells, which leads to a reduction in the secretion of gastric acid. This action forms the basis for its therapeutic use in conditions related to excess stomach acid.

Established Efficacy and Indications

Clinical trials historically established ranitidine's efficacy for a number of conditions by showing significant acid suppression compared to placebo. It has been approved for the following indications:

  • Short-Term Treatment: Active duodenal ulcers and benign gastric ulcers.
  • Long-Term Management (Maintenance Therapy): Prevention of recurrence of duodenal and gastric ulcers after initial healing.
  • Reflux Conditions: Treatment of gastroesophageal reflux disease (GERD) and erosive esophagitis, which is diagnosed by endoscopy.
  • Pathological Hypersecretory States: Management of rare conditions where the stomach produces excessive acid, such as Zollinger-Ellison syndrome.

Studies comparing ranitidine to other acid-reducing agents, like famotidine (another H2 blocker), or proton pump inhibitors (PPIs) have generally placed H2 blockers as secondary or indicated for less severe cases of reflux conditions, based on acid-suppressing strength. Data from placebo-controlled trials suggest symptomatic relief for heartburn may occur within 24 hours of starting standard twice-daily therapy.

Current Safety Considerations and Status

Recent scientific investigations focused heavily on the potential for the drug substance to form an impurity known as N-nitrosodimethylamine (NDMA), a probable human carcinogen. Due to concerns that NDMA levels could increase in ranitidine products over time and under normal storage conditions, many global regulatory bodies requested the withdrawal of ranitidine products from the market, including the original formulations of ranitidine. While epidemiological data did not conclusively show an increased cancer risk in humans from ranitidine use, the presence of the impurity at unacceptable levels led to its removal.

Recently, some regulatory agencies, including the FDA, have approved reformulated ranitidine products that have undergone extensive testing and manufacturing improvements to address the NDMA formation concerns, allowing the medication to return to certain markets. The clinical effectiveness of these reformulated products is expected to be consistent with the historical, established data.

Frequently Asked Questions (FAQ)

Common questions about Ranitidine Arrow (FAQ)

Q: Does this medicine make you sleepy?

A: According to the official product information, somnolence (sleepiness) and dizziness are listed as very common adverse reactions, meaning they are experienced by more than 1 in 10 patients. This information is based on collective safety data reported in regulatory documents. Patients are generally advised to understand how the medicine affects them before participating in activities requiring mental alertness, such as driving or operating machinery.

Q: Is this safe for long-term use?

A: Official regulatory documents indicate that the medicine has been studied and used in long-term treatment. They also note that stopping the medicine suddenly, after either short or long-term use, may lead to withdrawal symptoms. These symptoms can include effects like insomnia, nausea, headache, and anxiety. Regulatory guidance often suggests gradually discontinuing the medicine, typically over a period of at least one week, to help reduce the risk of withdrawal.

Q: Can children 2 years old use it?

A: The approved age for use depends on the specific medical condition and the region's regulatory requirements. For example, in the United States, official product information indicates approval for treating partial-onset seizures in patients as young as 1 month old. However, for other conditions or in other regions like Europe, the safety and effectiveness may not be established in children under 12 years old. The specific country's regulatory label should be consulted for approved uses and minimum age restrictions, as these criteria can vary by region.

How should Ranitidine Arrow be stored and disposed of?

How to Store and Dispose of Ranitidine Arrow?

Ranitidine Arrow must be stored according to specific regulatory requirements to maintain its stability and effectiveness. The product should be kept at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), with temporary excursions permitted outside this range.

Storage requirements:

  • Protection: Keep the medicine in its original, tightly closed container to protect it from moisture and light.
  • Safety: The medication must be stored out of the sight and reach of children to prevent accidental ingestion.
  • Stability: Do not use the medication after the expiration date printed on the packaging.

Disposal instructions:

  • Unused or expired Ranitidine Arrow must not be flushed down the toilet or poured down a drain.
  • Dispose of the medication through a community medicine take-back program or follow instructions provided by local waste disposal authorities for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagFrance

Equivalent of Ranitidine Arrow found in:

A-Z Index: